3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
A comprehensive, citation-dense breakdown of Rezdiffra (resmetirom) adverse events from MAESTRO-NASH, MAESTRO-NAFLD-1, FAERS reports, and the FDA prescribing label, with exact incidence rates by dose and trial arm.
A comprehensive clinical review of Rezdiffra (resmetirom) side effects, including potentially permanent adverse events, hepatic risks, trial data from MAESTRO-NASH, FDA labeling, and post-market surveillance findings.
A comprehensive clinical breakdown of Rezdiffra (resmetirom) adverse events by severity grade and patient phenotype, drawing on MAESTRO-NASH, FAERS data, and the FDA prescribing label.